Every egg maturation cycle and every sperm development program depends on a precise dose of follicle-stimulating hormone (FSH). FSH is a two-subunit hormone: the alpha subunit is shared with LH, TSH, and hCG, but the beta subunit (FSHB)¹¹ beta subunit (FSHB)
The beta subunit determines FSH's receptor-binding specificity — it is the component that targets FSH exclusively to ovarian granulosa cells and testicular Sertoli cells is unique to FSH and sets its production rate. The c.-211G>T variant sits in the FSHB promoter, 211 base pairs upstream of the transcription start site, and quietly reduces how much of this hormone the pituitary can make — with consequences that play out across a person's entire reproductive life.

The Mechanism

The G-to-T substitution at position -211 falls within a conserved binding site for LHX3²² LHX3
LIM homeobox transcription factor 3, expressed in pituitary gonadotroph cells; essential for FSH but not LH production, a homeodomain protein that drives basal FSHB expression in pituitary gonadotroph cells. Functional studies show that LHX3 binds with measurably lower affinity to the T-allele promoter, and when the T allele is tested in luciferase reporter assays, the promoter produces only 46–58% of the transcriptional output of the G allele³³ only 46–58% of the transcriptional output of the G allele
Measured in LβT2 gonadotroph cells using matched promoter constructs; reproduced independently by two research groups.

This reduced promoter activity translates directly into lower circulating FSH. The effect is additive: heterozygotes (GT) have roughly 13–16% less FSH than GG individuals, and TT homozygotes have approximately 40–50% less FSH⁴⁴ TT homozygotes have approximately 40–50% less FSH
Both figures replicated in independent Baltic, Estonian, and German cohorts; the Estonian study used n=554 healthy men. Because FSH drives Sertoli cell proliferation during fetal and neonatal development — a window that determines permanent testicular size and spermatogenic capacity — the effect on males extends well beyond adult hormone levels.

The Evidence

In males, the consequences of lifelong reduced FSH are measurable at the organ level. A large Baltic cohort study⁵⁵ A large Baltic cohort study
Grigorova et al., Genetically Determined Dosage of Follicle-Stimulating Hormone Affects Male Reproductive Parameters. JCEM, 2011 of 1,054 men showed that TT homozygotes had ~20% smaller testicular volume (38 mL vs 47 mL), 21% lower inhibin-B (a direct Sertoli cell product), and lower testosterone compared to GG carriers. FSH reduction per T allele was 0.51 IU/L in combined meta-analysis. The T allele was enriched among infertile men in multiple cohorts: one study of 1,029 infertile men and 554 fertile controls⁶⁶ one study of 1,029 infertile men and 554 fertile controls
Tüttelmann et al., JCEM, 2012 found TT genotype in 2.4% of infertile vs 1.1% of fertile men. In non-obstructive azoospermia patients undergoing TESE (testicular sperm extraction)⁷⁷ non-obstructive azoospermia patients undergoing TESE (testicular sperm extraction)
Busch et al., JCEM, 2019, the T allele significantly predicted failed sperm retrieval, an association that held even after adjusting for FSH levels — suggesting a direct effect on spermatogenesis beyond the hormonal signal alone.

In females, a large genetic association study using UK Biobank data (up to 63,350 women)⁸⁸ a large genetic association study using UK Biobank data (up to 63,350 women)
Ruth et al., Human Reproduction, 2016 demonstrated that each T allele lengthens the menstrual cycle by approximately 1 day (0.16 SD; P=6×10⁻¹⁶) and delays menopause by 0.13 years, consistent with lower FSH slowing ovarian follicle recruitment and depletion. The same T allele was protective against endometriosis⁹⁹ protective against endometriosis
OR 0.79, 95% CI 0.69–0.90; P=4.1×10⁻⁴; consistent with FSH's role in promoting estrogen production from developing follicles but increased the probability of nulliparity (OR 1.06), suggesting reduced conception efficiency. For women undergoing IVF, a Brazilian study (n=140)¹⁰¹⁰ a Brazilian study (n=140)
Trevisan et al., Genetic Testing and Molecular Biomarkers, 2019 found that GT carriers had significantly fewer antral follicles (8.0 vs 10.0; P=0.03), fewer oocytes retrieved (3.0 vs 5.0; P=0.03), and nearly double the rate of poor response to controlled ovarian stimulation (47.4% vs 26.5%; P=0.010).

Practical Implications

The T allele does not prevent fertility; it reduces FSH-driven amplification of the reproductive signal. For carriers planning assisted reproduction, this has direct protocol implications: lower baseline FSH may indicate a need for adjusted gonadotropin dosing. For male T-allele carriers, the implications are most acute in azoospermia evaluation — when TESE is being considered, the genotype may help predict sperm retrieval probability. The variant is also relevant in interpreting unexpectedly normal or low FSH in the context of reproductive difficulty: a "normal" FSH reading in a TT carrier may represent relative FSH insufficiency for that individual's gonadal needs.

Interactions

rs11031006 (FSHB distal enhancer): This batch includes both the proximal promoter variant (c.-211G>T, this SNP) and the distal enhancer SNP rs11031006, located ~26 kb upstream of the FSHB transcription start site. The two SNPs are in moderate linkage disequilibrium (r2 ~0.2–0.3 in Europeans) but have independent functional mechanisms: c.-211G>T impairs LHX3 binding at the proximal promoter, while rs11031006 affects SF1 binding at the distal enhancer. Both reduce FSH transcription via different regulatory inputs, and individuals carrying T alleles at both positions may experience a compounded reduction in FSH output that is not captured by either SNP alone. Direct compound analysis across both variants has not been published, but the additive pathway biology is well-established.

FSHR rs6166 (N680S) + FSHB rs10835638: When FSH production is already reduced (FSHB T allele) and the FSH receptor also operates at lower efficiency (FSHR rs6166 GG/Ser680Ser), the combined effect represents a dual impairment of the FSH axis — reduced signal and reduced receptor sensitivity. A published compound analysis of FSHB c.-211G>T and FSHR 2039A>G (rs6166) in 3,017 men confirmed that the FSHR variant significantly modulated the already-dominant FSHB T-allele effect on FSH and testicular volume. For IVF protocols, this dual-impairment signature may predict a lower-than-expected response to standard FSH stimulation doses and would warrant earlier dose escalation review. Proposed compound action: rs10835638 (GT or TT) + rs6166 (GG) — "Dual FSH Axis Impairment: Low Production and Reduced Receptor Sensitivity." Action type: monitoring + lifestyle (IVF protocol disclosure). Evidence level: moderate.

IRF1/RAD50 rs13164856 + FSHB rs10835638: rs13164856 is a PCOS-susceptibility tag SNP at 5q31 specifically associated with testosterone levels. Women carrying the rs13164856 T allele (androgen-excess) alongside the FSHB T allele (low FSH) may face compound reproductive challenges: elevated androgens combined with reduced FSH-driven follicle development. This represents two distinct PCOS pathways converging — androgen excess and gonadotropin insufficiency.

Inside every vascular smooth muscle cell, a molecular tug-of-war determines whether your blood vessels relax or contract. On one side: cyclic AMP (cAMP), a signalling molecule that promotes vasodilation. On the other: phosphodiesterase 3A (PDE3A)¹¹ phosphodiesterase 3A (PDE3A)
the enzyme that degrades cAMP and terminates its vasodilatory signal. The balance between cAMP production and degradation governs vascular tone, cardiac contractility, and platelet activation. The rs10841496 variant sits in the 5' untranslated region (5' UTR) of the PDE3A gene — a regulatory zone that influences how much protein the gene produces.

PDE3A gained clinical prominence when rare gain-of-function mutations in its coding sequence were found to cause an autosomal dominant syndrome of severe salt-independent hypertension with brachydactyly type E²² severe salt-independent hypertension with brachydactyly type E
shortened fingers and toes co-occur with dangerous blood pressure elevations in every affected family member. This rare syndrome crystallised the mechanism: when PDE3A is overactive, cAMP degrades too fast, vascular smooth muscle cells proliferate and cannot relax normally, and blood pressure climbs. The rs10841496 variant, by contrast, is common and operates at a regulatory level — potentially nudging PDE3A expression rather than altering the enzyme itself.

The Mechanism

The 5' UTR of a gene is not translated into protein but powerfully shapes how much protein gets made. 5' UTR sequences contain secondary structures, upstream open reading frames, and binding sites for RNA-binding proteins³³ 5' UTR sequences contain secondary structures, upstream open reading frames, and binding sites for RNA-binding proteins
these elements control ribosome loading and mRNA stability, affecting protein output without changing amino acid sequence. A variant here can increase or decrease steady-state PDE3A protein levels in vascular smooth muscle cells, cardiac myocytes, and platelets — the three tissues where PDE3A is most highly expressed.

PDE3A degrades both cAMP and cGMP. Elevated PDE3A activity blunts both the beta-adrenergic (cAMP) and nitric oxide (cGMP) vasodilatory pathways simultaneously. PDE3A-knockout mouse studies⁴⁴ PDE3A-knockout mouse studies
mice lacking PDE3A show reduced vascular smooth muscle cell proliferation and impaired mitogen-driven growth confirm that normal PDE3A activity is necessary for VSMC cell cycle progression — an activity that becomes pathological when the enzyme is overexpressed or hyperactive.

In platelets, PDE3A is the principal enzyme controlling intracellular cAMP. Cilostazol, a selective PDE3A inhibitor used clinically for peripheral arterial disease⁵⁵ Cilostazol, a selective PDE3A inhibitor used clinically for peripheral arterial disease
elevates platelet cAMP, suppressing aggregation and reducing pro-thrombotic extracellular vesicle release. Higher endogenous PDE3A expression could thus counteract this platelet-quiescent cAMP pool, tipping the balance toward greater platelet activation.

The Evidence

The strongest evidence linking this locus to blood pressure comes from population genetics. The 2015 trans-ancestry GWAS by Kato et al.⁶⁶ The 2015 trans-ancestry GWAS by Kato et al.
75,000+ participants of Asian, European, and African ancestry identified PDE3A as a methylation-enriched blood pressure locus — a finding replicated in a 2022 Chinese cohort study of 1,241 participants using Mendelian randomization, which confirmed that DNA methylation at PDE3A promoter CpG sites is causally associated with blood pressure variation ⁷⁷ PMID 35087571.

At the pharmacogenomics level, Iniesta et al. (2019)⁸⁸ Iniesta et al. (2019)
4,696 participants across five antihypertensive drug trials found that PDE3A locus variants explained differences of −3.5 to +3.5 mmHg per allele in blood pressure response to candesartan (ARB) and hydrochlorothiazide (thiazide), with differential effects between Black and White participants. This suggests the PDE3A locus influences not just baseline blood pressure but also the pharmacological response to antihypertensive medication.

The specific functional consequence of rs10841496 — a C>A transversion in the 5' UTR — remains incompletely characterised at the molecular level. No published study has directly measured PDE3A expression as a function of this genotype. The evidence for blood pressure effects is therefore indirect, resting on locus-level GWAS associations rather than variant-resolved mechanistic data. This places the evidence at the emerging level for this specific SNP.

One additional signal: rs10841496 was identified among variants significantly associated with semen quality parameters in a Han Chinese case-control study ⁹⁹ 136 subfertile men versus 456 fertile controls, consistent with PDE3A's known role in regulating sperm motility through cAMP signalling in flagellar dynein.

Practical Actions

Carriers of the AA genotype may experience modestly altered PDE3A expression, with downstream effects on vascular tone and platelet reactivity. Given the locus-level evidence for blood pressure effects, cardiovascular monitoring is the most evidence- grounded action. If blood pressure is borderline or elevated, the PDE3A locus evidence suggests cilostazol (a PDE3A inhibitor) or antihypertensive agents targeting the renin-angiotensin-aldosterone system may be particularly relevant — though the pharmacogenomic data are insufficient to override standard prescribing guidelines.

Maintaining healthy nitric oxide (NO) signalling — which activates cGMP — can partially compensate for elevated PDE3A activity. Dietary nitrates from vegetables such as beetroot, rocket, and spinach raise plasma nitrite and enhance NO bioavailability through the nitrate-nitrite-NO pathway, bypassing dependence on eNOS enzymatic activity.

Interactions

PDE3A shares the cyclic nucleotide degradation network with PDE3B (expressed in adipose and liver), PDE4 isoforms (dominant in many immune and vascular cells), and PDE5 (the cGMP-specific enzyme). Variants in NOS3 (rs1799983, eNOS Glu298Asp) reduce nitric oxide synthesis — the primary driver of cGMP — and would compound any PDE3A-mediated acceleration of cGMP degradation. Carrying both a reduced-NOS3 and elevated-PDE3A genotype could meaningfully amplify vasoconstrictive tone.

The GWAS locus at 12p12.2 where PDE3A sits spans several nearby genes; the full causal variant(s) in this region have not been resolved to single-SNP resolution. Future fine-mapping studies may clarify whether rs10841496 is a causal regulatory variant or a tag for the true functional allele.

Endometriosis — in which tissue resembling the uterine lining implants and grows outside the uterus — affects approximately 10% of women of reproductive age and accounts for a disproportionate burden of pelvic pain, dyspareunia, infertility, and diagnostic delay. The condition is strongly heritable; genetic factors explain roughly 50% of susceptibility variance. rs10859871, an intronic variant near the VEZT gene at chromosome 12q22, is one of the most robustly replicated genome-wide association signals for endometriosis, confirmed across multiple independent datasets in European and Japanese populations.

VEZT encodes vezatin¹¹ vezatin
a ubiquitous transmembrane protein of adherens junctions — the intercellular adhesion structures that link neighboring epithelial and endothelial cells via the cadherin–catenin–actin axis. Vezatin is a 779 amino acid protein embedded in the transmembrane domain of adherens junctions; it interacts with myosin VIIa and the cadherin–catenin complex to stabilize cell-cell contacts and regulate cytoskeletal tension. Disruption of adherens junction integrity is a recognized feature of endometriotic stromal cells, enabling the detachment, peritoneal transit, and ectopic re-implantation that characterize endometriosis.

The Mechanism

rs10859871 sits in an intron of VEZT and does not alter the vezatin protein sequence. Its clinical relevance lies in its function as a cis-eQTL²² cis-eQTL
an expression quantitative trait locus — a genetic variant that regulates the expression level of a nearby gene in cis, meaning on the same chromosome. The endometriosis risk allele (C) is associated with increased VEZT mRNA levels in both blood and endometrial tissue, as demonstrated by Holdsworth-Carson et al. using samples from 228 women across four endometrial compartments. This upregulation suggests that the C allele alters transcription factor binding or chromatin accessibility at the intronic locus, shifting vezatin expression toward levels that may paradoxically destabilize adherens junction dynamics rather than reinforce them — possibly through titrating junction components or activating feedback suppression.

In endometriotic stromal cells, adherens junction weakening reduces E-cadherin-mediated cohesion, facilitating epithelial–mesenchymal transition and invasive behavior analogous to metastatic cancer cells. Vezatin's role in connecting myosin VIIa to the cadherin complex places it at the intersection of mechanosensing and junction stability: altered vezatin levels could shift the balance between adhesion and contractility-driven detachment in endometrial cells shed during retrograde menstruation. Protein-level confirmation of the eQTL effect in endometrial tissue has not yet been published, and functional studies directly testing vezatin's causal role in endometriosis pathogenesis remain warranted.

The Evidence

The initial genome-wide significant association was reported by Nyholt et al. in Nature Genetics (2012)³³ Nyholt et al. in Nature Genetics (2012)
GWAS meta-analysis of 4,604 cases and 9,393 controls from Japanese and European cohorts identified seven endometriosis loci; rs10859871 at 12q22/VEZT reached P = 5 × 10⁻¹³, OR ~1.2 (95% CI 1.14–1.26). The signal was independent of the other known endometriosis loci and consistent across both ancestral groups studied.

A subsequent replication and meta-analysis by Pagliardini et al. (Human Reproduction, 2015)⁴⁴ replication and meta-analysis by Pagliardini et al. (Human Reproduction, 2015)
confirmed rs10859871 as the locus with the single strongest statistical support for endometriosis association; OR = 1.19, P = 7.9 × 10⁻²⁰ across combined datasets. Effect sizes were stronger in Stage III/IV disease than in milder stages, suggesting this locus is particularly implicated in moderate-to-severe and ovarian disease.

The Rahmioglu et al. meta-analysis (Human Reproduction Update, 2014)⁵⁵ Rahmioglu et al. meta-analysis (Human Reproduction Update, 2014)
11,506 cases and 32,678 controls across eight GWAS datasets; rs10859871 genome-wide significant at P = 4.7 × 10⁻¹⁵; all nine replicated loci showed stronger effects in Stage III/IV reached the same conclusion. The C allele's effect is consistent across European and East Asian populations, adding cross-ancestry evidence to the association.

A systematic review of endometriosis GWAS studies (Cardoso et al., 2020)⁶⁶ systematic review of endometriosis GWAS studies (Cardoso et al., 2020)
15 studies reviewed; VEZT rs10859871 was one of five variants highlighted as having the highest frequency of replication across independent datasets ranked rs10859871 among the five most consistently replicated endometriosis genetic signals alongside WNT4, GREB1, FN1, and IL1A loci.

Practical Implications

Carrying the C allele at rs10859871 confers a modest but well-established increase in endometriosis susceptibility, with an odds ratio of approximately 1.19 per C allele. The absolute risk contribution of a single locus is modest relative to the condition's overall ~10% population prevalence, but this signal combines additively with risk alleles at other confirmed loci (WNT4, GREB1, FN1, CDKN2B-AS1, IL1A, and HOXA10/11 loci).

The clearest clinical implication is awareness: the diagnostic delay for endometriosis averages 4–11 years from symptom onset, and genetic risk signals support a lower threshold for specialist evaluation when relevant symptoms are present. C allele carriers with symptoms consistent with endometriosis benefit from proactive gynecological referral rather than normalization of pelvic pain.

Interactions

rs7521902 (WNT4 locus, 1p36.12): WNT4 regulates Müllerian duct development and ovarian sex-steroid production. WNT4 and VEZT risk alleles are among the most replicated endometriosis loci; additive polygenic burden across these loci is expected under the established polygenic architecture, though formal interaction testing between rs10859871 and rs7521902 has not been published.

rs13394619 (GREB1, 2p25.1): GREB1 is an estrogen-responsive gene involved in endometrial proliferation. The combination of GREB1 and VEZT risk alleles likely contributes additively to endometriosis susceptibility through distinct pathways (hormonal regulation vs. adhesion junction mechanics).

rs1537377 (CDKN2B-AS1/ANRIL, 9p21.3): This locus near the cell-cycle regulatory genes CDKN2A/CDKN2B on chromosome 9 is a separate endometriosis GWAS signal. The CDKN2B-AS1 locus and the VEZT locus represent distinct genetic contributions to endometriosis risk — both have been confirmed in the same multi-locus meta-analyses.

rs1250248 (FN1, 2q34): The fibronectin gene is a confirmed endometriosis locus with particularly strong effects in Stage III/IV disease. Fibronectin-mediated ECM remodeling and vezatin-mediated adherens junction regulation both affect how ectopic endometrial cells adhere, invade, and persist — pathway-level convergence between these two loci is plausible.

At the heart of the innate immune system sits a protein called IRF5 (Interferon Regulatory Factor 5)¹¹ IRF5 (Interferon Regulatory Factor 5)
A master transcription factor that, when activated by viral or microbial signals, enters the cell nucleus and switches on genes for type I interferons and pro-inflammatory cytokines including TNF-α, IL-6, and IL-12. IRF5 is the key decision-maker that determines how vigorously your immune system responds to threats — but when it runs too high chronically, it becomes a driver of autoimmune disease. The rs10954213 variant, located in the 3' untranslated region of the IRF5 gene, is the best-characterized causal variant in one of genetics' most replicated autoimmune susceptibility loci. Unlike the nearby rs2004640 variant (which alters mRNA splicing) and rs2280714 (which is a tag SNP in linkage disequilibrium), rs10954213 directly controls how long the IRF5 messenger RNA survives in the cell — and therefore how much IRF5 protein gets made.

The Mechanism

The rs10954213 variant works through a process called alternative polyadenylation²² alternative polyadenylation
A mechanism by which the same gene can produce mRNA molecules of different lengths from the same 3' end; the cell's RNA-processing machinery recognizes a signal sequence (AAUAAA) and cleaves the mRNA at that point, adding a poly-A tail that protects the mRNA from degradation. The A allele of rs10954213 creates a canonical AAUAAA polyadenylation signal approximately 100 nucleotides upstream of the default cleavage site. When this proximal signal is present, the cell's polyadenylation machinery cleaves the mRNA at that upstream position, producing a shorter 3'-UTR isoform. This shorter transcript has two important properties: it escapes microRNA-mediated degradation³³ microRNA-mediated degradation
MicroRNAs are small RNA molecules that bind to complementary sequences in the 3'-UTR and mark mRNA transcripts for degradation; the longer 3'-UTR contains more such binding sites, making the longer isoform less stable that would normally limit IRF5 protein levels, and it accumulates in the cytoplasm at higher concentrations.

The G allele disrupts this proximal polyadenylation signal, forcing the cell to use a more distal cleavage site. The resulting longer 3'-UTR is less stable and contains more miRNA target sites, leading to lower IRF5 protein output. The UK SLE families study⁴⁴ UK SLE families study
Cunninghame Graham et al., Human Molecular Genetics 2007; 380 SLE nuclear families from the United Kingdom identified rs10954213 as the functional element with the strongest correlation to IRF5 mRNA expression levels (P=1×10⁻¹⁴). Consistent with its role as a proximate causal variant, rs10954213-A is in tight linkage disequilibrium with rs2280714-T (r²=0.79, D'=1.0), meaning that population studies using rs2280714 as a tag SNP are effectively measuring the same functional signal.

The Evidence

The most direct functional evidence comes from lymphoblastoid cell line studies across three ancestral populations. The Rullo et al. study⁵⁵ Rullo et al. study
Ann Rheum Dis 2010; lymphoblastoid cells from CEU (European), CHB+JPT (East Asian), and YRI (Yoruba Nigerian) populations from the HapMap project showed that IRF5 mRNA levels were consistently elevated in A-allele carriers compared to G/G homozygotes, with approximately 1.7-fold higher expression in Europeans — a pattern that held across all three ancestral groups tested. Critically, this elevated mRNA translated to elevated production of type I interferons (IFN-α) and IFN-inducible chemokines, directly linking the mRNA stability effect to downstream immune output.

For systemic lupus erythematosus (SLE), the rs10954213-A allele is part of the TAT risk haplotype (rs2004640-T / rs10954213-A / rs2280714-T) that has been replicated across more than 28 studies. A meta-analysis of these studies⁶⁶ meta-analysis of these studies
Systemic review: 11,228 SLE cases and 14,374 controls; Bentham et al. Nature Genetics 2019 found overall OR=1.39 for the T allele at rs2004640 (the haplotype tag), with the combined haplotype signal reaching P=2.11×10⁻¹⁶ when the Korean replication data are pooled across ancestries. The A allele's contribution is functional: Niewold et al.⁷⁷ Niewold et al.
Ann Rheum Dis 2012; 200+ SLE patients and controls showed that IRF5 haplotypes carrying rs10954213-A explained over 70% of genetic risk for elevated serum IFN-α, and were specifically linked to production of anti-dsDNA and anti-Ro autoantibodies — the hallmark autoantibodies that drive kidney and skin disease in lupus.

Beyond SLE, the rs10954213-A haplotype is associated with systemic sclerosis (scleroderma). A Japanese cohort study⁸⁸ Japanese cohort study
Furukawa et al. 2010; 283 SSc cases, 279 controls found that the IRF5 3' haplotype showed an OR of 1.42 (95% CI 1.15–1.75, P=0.0012), with preferential enrichment in the most severe disease subtypes — diffuse cutaneous SSc and anti-topoisomerase I antibody-positive disease. This indicates that higher IRF5 expression drives not only susceptibility but also disease severity and phenotype in scleroderma.

Practical Implications

For individuals carrying one or two copies of the A allele, the practical implication is that your innate immune system has a modestly elevated baseline interferon output and a lower threshold for sustaining interferon responses. This does not mean autoimmune disease is inevitable — most A allele carriers remain healthy — but it means earlier recognition and evaluation of symptoms is more important than it would be for GG individuals. The autoimmune conditions most closely linked to this variant are SLE, systemic sclerosis, and Sjögren syndrome. Early diagnosis of these conditions is critical: treatment initiated before significant organ damage dramatically improves long-term outcomes for all three conditions.

For AA homozygotes, the risk picture is more significant. Both chromosomes produce the shorter, high-stability IRF5 mRNA isoform. In the context of concurrent rs2004640-T and rs4728142 indel risk alleles (the full TAT haplotype), the combined effect on IRF5 expression can be substantial, and proactive monitoring with a rheumatologist becomes more medically justified. Serum IFN-α levels in TAT-homozygous SLE patients can be up to 7.6-fold above those seen in protective-genotype individuals, a molecular signature that is measurable and tracked in specialty centers.

Interactions

The rs10954213 variant sits within the broader IRF5 haplotype architecture alongside two other functional elements: rs2004640 (splice site variant enabling alternative exon 1B, increasing IRF5 isoform diversity) and rs4728142 (promoter CGGGG indel that increases SP1 transcription factor binding and IRF5 baseline transcription). Together these three elements drive IRF5 dysregulation at three levels — transcription, splicing, and mRNA stability — and individuals carrying all three risk alleles show the highest IRF5 output and autoimmune risk.

Additionally, IRF5 interacts additively with STAT4 (rs7574865), which sits downstream of IRF5 in the interferon signaling cascade. While IRF5 controls interferon production, STAT4 controls how sensitively immune cells respond to those interferons. Individuals with risk alleles at both loci can reach substantially amplified autoimmune risk — up to OR=6.78 with five combined IRF5+STAT4 risk alleles in Sjögren syndrome — reflecting a feed-forward amplification loop in interferon signaling.

The macula — the central region of the retina that provides high-acuity color vision — is one of the few human tissues that concentrates specific dietary pigments. Lutein and zeaxanthin accumulate there from the blood, forming the macular pigment¹¹ macular pigment
The yellow pigment at the center of the retina; it filters blue light, quenches reactive oxygen species from photo-oxidation, and protects photoreceptors from damage. Its optical density (MPOD) is measurable non-invasively and correlates with reduced age-related macular degeneration risk. The amount that reaches the macula depends on how much enters your circulation — and that, in turn, depends heavily on SR-BI (scavenger receptor class B type I), the intestinal and hepatic receptor encoded by SCARB1.

rs11057841 is an intronic variant in SCARB1 that tags a functional haplotype influencing this receptor's efficiency for fat-soluble carotenoid uptake. The T allele is associated with substantially higher serum lutein: a study of 302 healthy adults²² study of 302 healthy adults
McKay GJ et al. Investigation of genetic variation in scavenger receptor class B, member 1 (SCARB1) and association with serum carotenoids. Ophthalmology, 2013 found 24% more serum lutein per T allele, with the association surviving permutation correction (P<0.01) and replicating independently in both TwinsUK (P=0.014) and CAREDS cohorts. The majority of people carry two copies of the C allele and absorb carotenoids at the lower end of this range.

The Mechanism

SR-BI is expressed in both intestinal enterocytes and hepatocytes, where it mediates the selective uptake³³ selective uptake
Unlike receptor-mediated endocytosis, selective uptake extracts lipid cargo from HDL particles at the cell surface without internalizing the particle itself — the HDL docks, transfers its lipid payload through the receptor's hydrophobic tunnel, and departs intact of fat-soluble molecules from HDL particles⁴⁴ HDL particles
High-density lipoprotein; the particle class that transports dietary fat-soluble vitamins and carotenoids from the intestine through the lymphatic system and circulation to target tissues. A critical structural feature is a hydrophobic membrane tunnel through which lipophilic molecules pass into the cell. As Li et al. 2023⁵⁵ Li et al. 2023
Li Y et al. SR-BI's hydrophobic tunnel is the structural basis for selective macular carotenoid uptake. J Lipid Res, 2023 showed, this tunnel is specifically optimized for xanthophyll carotenoids (lutein, zeaxanthin): blocking it selectively abolishes uptake of these macular pigment precursors while leaving beta-carotene absorption less affected.

The importance of SR-BI for overall carotenoid and vitamin E absorption is profound. Reboul et al. 2006⁶⁶ Reboul et al. 2006
Reboul E et al. Scavenger receptor class B type I (SR-BI) is involved in vitamin E transport across the enterocyte. J Biol Chem, 2006 showed that pharmacological SR-BI blockade reduces intestinal alpha-tocopherol transport by up to 80% in cell models and mice. The same receptor handles beta-carotene and the macular xanthophylls. A haplotype tagged by rs11057841 that reduces SR-BI function would therefore affect the full suite of HDL-associated fat-soluble micronutrient absorption.

The Evidence

The primary evidence for rs11057841 comes from two independent lines of investigation. First, serum lutein levels: McKay et al. studied SCARB1 polymorphisms in 302 healthy subjects aged 20–70 and found rs11057841 to be the strongest SCARB1 signal for circulating lutein — 24% higher per T allele after multiple-testing correction. The linked SNP rs10846744 (r² = 0.93 with rs11057841) provided independent replication in CAREDS (P = 2×10⁻⁴), suggesting the same functional haplotype drives the association across studies.

Second, macular pigment: the downstream question is whether serum lutein differences translate to differences in tissue accumulation at the macula. Yonova-Doing et al. 2013⁷⁷ Yonova-Doing et al. 2013
Yonova-Doing E et al. Candidate gene study of macular response to supplemental lutein and zeaxanthin. Exp Eye Res, 2013 found that rs11057841 associated with both baseline serum lutein (P=0.01) and with macular pigment optical density (MPOD) response to supplementation (P<0.05) in 310 TwinsUK subjects. A more recent study of 108 twins by Kunceviciene et al. 2023⁸⁸ Kunceviciene et al. 2023
Kunceviciene E et al. Twins' macular pigment optical density assessment and relation with SCARB1 gene polymorphism. Genes (Basel), 2023 directly measured MPOD and found that CT heterozygotes had statistically significantly lower MPOD in both eyes (right: 0.110 vs. 0.117, P=0.037; left: 0.109 vs. 0.114, P=0.038) compared to CC homozygotes — an unexpected finding given that CC is the lower-absorption genotype, possibly reflecting the small sample size (n=6 CT vs. n=25 CC). The overall picture is consistent: the T allele haplotype improves lutein delivery from diet to blood to macula.

This variant is in partial linkage disequilibrium (r² ≈ 0.7) with rs11057830, the neighboring SCARB1 variant associated with circulating alpha-tocopherol (vitamin E) at genome-wide significance. The two SNPs likely tag overlapping but not identical functional signals within the same SCARB1 haplotype block — rs11057841 is more strongly associated with carotenoids while rs11057830 has a stronger vitamin E signal.

Practical Implications

For CC homozygotes — approximately 71% of people — lower SR-BI-mediated carotenoid uptake means the conversion of dietary lutein and zeaxanthin into circulating and macular levels is less efficient. This is clinically meaningful because macular pigment acts as the retina's primary optical filter against blue light and oxidative photo-damage. Age-related macular degeneration (AMD)⁹⁹ Age-related macular degeneration (AMD)
The leading cause of irreversible vision loss in adults over 50, AMD involves progressive degeneration of the central macula. Macular pigment levels are consistently lower in AMD patients, and lutein/zeaxanthin supplementation slows progression in the intermediate stage (AREDS2 trial) risk increases with lower macular pigment.

Two strategies directly counteract reduced SR-BI efficiency. First, increasing dietary lutein and zeaxanthin density: the receptor can deliver more when more substrate is available. Kale, spinach, and egg yolks are the densest sources. Second, cooking and fat pairing: SR-BI requires that carotenoids be dissolved in fat micelles to access the receptor's uptake tunnel. Cooked (rather than raw) carotenoid-rich vegetables in the presence of fat increase bioaccessibility 3–6 fold.

Interactions

rs11057841 tags the carotenoid end of the SCARB1 functional haplotype, while nearby rs11057830 (r² ≈ 0.7) tags the vitamin E (alpha-tocopherol) end. Both represent reduced SR-BI function, so CC carriers at rs11057841 who are also GG at rs11057830 face compound reductions in both carotenoid and tocopherol absorption through this receptor — the two signals are partially independent, and the combined picture is more actionable than either alone.

A downstream interaction involves rs12934922 in BCO1 (beta-carotene 15,15'-oxygenase): rs11057841 CC determines how much dietary beta-carotene enters the body via SR-BI, while BCO1 rs12934922 determines how efficiently it is converted to retinol. Individuals who are CC at rs11057841 and carry the low-conversion BCO1 genotype absorb less beta-carotene AND convert less of it to vitamin A — a downstream compound effect that would warrant attention to preformed vitamin A sources.

Interleukin-1 beta (IL-1β) is one of the most potent pro-inflammatory cytokines in the body — it initiates fever, activates immune cells, induces other cytokines, and drives inflammation in virtually every tissue. The rs1143627 variant sits just 31 base pairs upstream of the IL1B transcription start site, in a region that directly controls how vigorously your immune cells turn on IL-1β production. The IL1B gene sits on the minus strand¹¹ The IL1B gene sits on the minus strand
On the plus strand, this variant is G→A; the coding-strand notation -31T>C reflects the minus-strand complement.

The Mechanism

The -31 position lies within the TATA-box region of the IL1B promoter²² TATA-box region of the IL1B promoter
The TATA box is a core promoter element recognized by transcription factor TFIID, which recruits RNA polymerase to begin transcription. The T allele (A on the genomic plus strand) creates a binding site configuration that permits higher basal and stimulated IL-1β transcription. When macrophages and dendritic cells encounter bacteria, viruses, or crystals (such as urate or cholesterol), the T-allele variants mount a more vigorous IL-1β response — producing more cytokine for the same immune stimulus.

This promoter variant is in near-complete linkage disequilibrium with the -511C>T variant (rs16944)³³ near-complete linkage disequilibrium with the -511C>T variant (rs16944)
The two promoter SNPs are almost always inherited together as a haplotype, so their effects are highly correlated in most populations. However, rs1143627 sits closer to the transcription start site and may independently influence transcription factor binding at the TATA box.

The Evidence

The clearest association is with gastric cancer in the context of H. pylori infection. A meta-analysis of 37 studies (6,108 cases, 8,980 controls) found the -31T allele increases gastric cancer risk specifically in H. pylori-positive individuals⁴⁴ meta-analysis of 37 studies (6,108 cases, 8,980 controls) found the -31T allele increases gastric cancer risk specifically in H. pylori-positive individuals
Homozygous model: OR = 1.35 (95% CI 1.02-1.78); heterozygous model: OR = 1.31 (1.04-1.66); recessive model: OR = 1.29 (1.04-1.61). The interaction is mechanistically plausible: H. pylori triggers massive NLRP3 inflammasome activation, releasing IL-1β; the -31T variant amplifies this IL-1β surge, creating a chronically inflamed gastric mucosa that accelerates progression from gastritis to metaplasia to carcinoma.

At the tissue level, H. pylori-positive dyspepsia patients with the TT genotype had 2.25-fold higher odds of moderate-to-severe chronic antral inflammation compared to CC+CT carriers (80.8% vs. 65.2%, OR = 2.25, 95% CI 1.23-4.24, p = 0.005)⁵⁵ H. pylori-positive dyspepsia patients with the TT genotype had 2.25-fold higher odds of moderate-to-severe chronic antral inflammation compared to CC+CT carriers (80.8% vs. 65.2%, OR = 2.25, 95% CI 1.23-4.24, p = 0.005), directly demonstrating how the variant amplifies inflammatory damage in infected stomachs.

Chronic periodontitis shows a parallel pattern. In an Indian case-control study (157 periodontitis patients, 200 controls), IL1B -31C/T was significantly associated with increased susceptibility to chronic periodontitis⁶⁶ In an Indian case-control study (157 periodontitis patients, 200 controls), IL1B -31C/T was significantly associated with increased susceptibility to chronic periodontitis
The variant was also part of the optimal gene-gene interaction model for disease risk alongside IL1B +3954 and IL-10 -819. Bacteria in subgingival plaque trigger the same NLRP3-IL-1β axis that H. pylori activates in the stomach; genetically amplified IL-1β production accelerates periodontal bone destruction.

In Kawasaki disease, children under 12 months with the AA genotype at rs1143627 had 2.28-fold increased risk of coronary artery lesions (OR = 2.28, 95% CI 1.32-3.95, p = 0.0032), with the adjusted OR reaching 2.33 in 719 KD patients and 1,401 healthy controls from southern China ⁷⁷ children under 12 months with the AA genotype at rs1143627 had 2.28-fold increased risk of coronary artery lesions (OR = 2.28, 95% CI 1.32-3.95, p = 0.0032), with the adjusted OR reaching 2.33 in 719 KD patients and 1,401 healthy controls from southern China . This implicates high IL-1β production in amplifying the vasculitis that damages coronary arteries in this disease.

In transplantation immunology, rs1143627 was significantly associated with acute graft-versus-host disease grade II-IV in pediatric HSCT recipients (p = 0.019)⁸⁸ rs1143627 was significantly associated with acute graft-versus-host disease grade II-IV in pediatric HSCT recipients (p = 0.019)
Carriers of risk alleles combined with HLA-B*15:01 had hazard ratio 2.14 (95% CI 1.41-3.25, p = 6×10⁻⁶), confirming the variant's role in driving severe alloimmune inflammation.

Practical Actions

For carriers of the A allele (T in coding notation), the most actionable implications are:

Gastrointestinal health: H. pylori testing is especially important. If H. pylori is detected, eradication should be prompt and confirmed — the combination of this variant and active infection creates the gene-environment interaction that most dramatically elevates gastric cancer risk. After eradication, periodic upper endoscopy surveillance is warranted if there is a family history of gastric cancer or if atrophic gastritis was found.

Periodontal vigilance: The genotype amplifies periodontal inflammation in the presence of dysbiotic gingival flora. More frequent professional cleaning (every 3-4 months rather than 6) and diligent home plaque control directly reduce the bacterial trigger for IL-1β release.

Systemic inflammation monitoring: Elevated IL-1β drives IL-6 production, which raises hsCRP. Tracking high-sensitivity CRP as part of routine health assessments captures the downstream inflammatory state this variant promotes.

Interactions

This variant is in near-complete linkage disequilibrium with rs16944 (-511C>T), the other well-studied IL1B promoter polymorphism. They are typically inherited together as the -511T/-31T haplotype (A/A on the plus strand), which compounds expression effects. The IL-1 gene cluster also includes IL1A (rs1800587) and IL1RN (interleukin-1 receptor antagonist); variants in IL1RN that reduce the IL-1 receptor antagonist can amplify net IL-1β biological activity even further⁹⁹ variants in IL1RN that reduce the IL-1 receptor antagonist can amplify net IL-1β biological activity even further
IL-1Ra normally dampens IL-1β signaling by competitive receptor binding.

Most people have never heard of ACAD9, yet it plays two essential roles inside every energy-demanding cell in the body. The protein encoded by ACAD9 — acyl-CoA dehydrogenase family member 9 — acts simultaneously as an enzyme that oxidizes long-chain fatty acids¹¹ enzyme that oxidizes long-chain fatty acids
Long-chain fatty acid oxidation (FAO) converts fat into acetyl-CoA for ATP production; ACAD9 specifically processes very-long-chain acyl-CoA substrates and as an indispensable assembly factor for mitochondrial complex I²² assembly factor for mitochondrial complex I
Complex I (NADH:ubiquinone oxidoreductase) is the first and largest enzyme of the mitochondrial electron transport chain; it transfers electrons from NADH to ubiquinone, pumping protons to drive ATP synthesis. Complex I deficiency is the most common cause of respiratory chain disease in humans. When the Ala326Pro variant disables ACAD9, both functions collapse, and the mitochondrial power supply to the heart, brain, and muscles is severely compromised.

The Mechanism

The c.976G>C substitution (rs115532916) replaces the flexible amino acid alanine at position 326 with the rigid cyclic amino acid proline. Proline is famously disruptive to alpha-helices and beta-sheets — it introduces a kink that few protein structures can accommodate. In ACAD9, this structural disruption abolishes ACAD enzyme activity³³ ACAD enzyme activity
Acyl-CoA dehydrogenase (ACAD) enzymes catalyze the alpha,beta-dehydrogenation of acyl-CoA esters; ACAD9 specifically targets long-chain (C12–C18) substrates, confirmed by functional studies cited in ClinVar and the Schiff et al. analysis of 16 ACAD9 variants.

The loss of ACAD9 protein function also depletes the complex I assembly scaffold. ACAD9 interacts with ECSIT and NDUFAF1⁴⁴ ECSIT and NDUFAF1
ECSIT (evolutionarily conserved signaling intermediate in Toll pathway) and NDUFAF1 (NADH:ubiquinone oxidoreductase complex assembly factor 1) form a trimeric complex with ACAD9 that nucleates the assembly of complex I's membrane arm, and in the absence of functional ACAD9, complex I cannot be fully assembled. The result is a profound biochemical energy deficit: cells cannot efficiently oxidize fats and cannot run the electron transport chain at capacity.

The Evidence

Haack et al. (2010, Nature Genetics)⁵⁵ Haack et al. (2010, Nature Genetics)
Haack TB et al. Exome sequencing identifies ACAD9 mutations as a cause of complex I deficiency. Nat Genet, 2010 established ACAD9 as a complex I deficiency gene using whole-exome sequencing. The original patient carrying Ala326Pro (in compound heterozygosity with a second ACAD9 variant, R532W) developed hypertrophic cardiomyopathy, encephalomyopathy, and lactic acidosis, with muscle complex I activity reduced to 26% of normal. That child died at age two. Restoring wild-type ACAD9 in patient-derived fibroblasts rescued complex I activity, confirming the causal role.

Schiff et al. (2015, Human Molecular Genetics)⁶⁶ Schiff et al. (2015, Human Molecular Genetics)
Schiff M et al. Complex I assembly function and fatty acid oxidation enzyme activity of ACAD9 both contribute to disease severity in ACAD9 deficiency. Hum Mol Genet, 2015 analyzed 16 ACAD9 mutations across 24 patients and found a significant inverse correlation between residual ACAD enzyme activity and phenotypic severity. Both the enzymatic and scaffolding functions are clinically relevant — variants that eliminate only one function produce milder disease than those that eliminate both.

ClinVar lists this variant (VCV000030883) as Pathogenic/Likely pathogenic, with 8 of 9 submissions in agreement across nine independent diagnostic centers including GeneDx, Invitae, Great Ormond Street Hospital, and Baylor Genetics.

A therapeutically important subset of ACAD9 patients responds to high-dose riboflavin⁷⁷ riboflavin
Riboflavin (vitamin B2) is the precursor of FAD (flavin adenine dinucleotide), the essential cofactor bound by ACAD enzyme active sites. In riboflavin-responsive patients, supplemental B2 appears to stabilize residual ACAD9 protein and partially restore complex I assembly (vitamin B2). Gerards et al. (2011, Brain)⁸⁸ Gerards et al. (2011, Brain)
Gerards M et al. Riboflavin-responsive oxidative phosphorylation complex I deficiency caused by defective ACAD9. Brain, 2011 reported improved exercise tolerance and complex I activity in riboflavin-treated ACAD9 patients. However, Nouws et al. (2014)⁹⁹ Nouws et al. (2014)
Nouws J et al. A Patient with Complex I Deficiency Caused by a Novel ACAD9 Mutation Not Responding to Riboflavin Treatment. JIMD Rep, 2014 documented a fatal case where riboflavin supplementation had no effect, indicating that response is mutation-dependent. Variants that cause protein instability (rather than cofactor insufficiency) do not respond. The Ala326Pro variant causes loss of enzyme activity, so responsiveness must be assessed biochemically in each affected individual.

Practical Actions

Because ACAD9 deficiency is autosomal recessive, heterozygous carriers — one Ala326Pro allele plus one normal allele — have sufficient ACAD9 function and do not develop ACAD9 deficiency. The primary clinical significance of heterozygous carrier status is reproductive. If both parents carry a pathogenic ACAD9 variant, each pregnancy has a 25% chance of being affected.

Homozygous or compound heterozygous patients require urgent specialist management. A trial of high-dose riboflavin under metabolic specialist supervision is standard practice, with biochemical response assessed before and after supplementation. Additional interventions studied in riboflavin-non-responsive cases include bezafibrate and nicotinamide riboside, with limited but preliminary evidence of transient benefit.

Interactions

ACAD9 deficiency is caused by biallelic pathogenic variants — two mutations must be present to cause disease. The Ala326Pro variant is documented in compound heterozygosity with R532W in the original Haack et al. case. Any second pathogenic ACAD9 allele combined with Ala326Pro would be expected to produce ACAD9 deficiency. Genetic counseling should characterize both ACAD9 alleles in any suspected case.

Hidden in the machinery that controls cell division is an unexpected player in coronary artery disease. The ZC3HC1 gene¹¹ ZC3HC1 gene
encodes NIPA — Nuclear Interaction Partner of ALK — a protein that governs when cells transition into mitosis by controlling the nuclear accumulation of cyclin-B1, the key trigger of cell division. The rs11556924 variant swaps a single amino acid at position 363 — arginine to histidine — and this seemingly small change has genome-wide significant consequences for coronary artery disease risk.

This locus is unusual among cardiovascular GWAS hits. Most CAD-associated variants sit in regulatory regions of uncertain function, but rs11556924 is a direct coding change: the only nonsynonymous SNP in the landmark CARDIoGRAM consortium meta-analysis²² CARDIoGRAM consortium meta-analysis
22,233 CAD cases and 64,762 controls of European ancestry that identified 13 new susceptibility loci. The T allele (His363) carries an odds ratio of 0.90 for CAD — a 10% reduction in risk per allele — with a p-value of 2.4×10⁻¹⁷.

The Mechanism

NIPA acts as a molecular brake on mitotic entry. In dividing cells, cyclin-B1 must accumulate in the nucleus before cell division can proceed. NIPA controls the rate of this nuclear entry by responding to CDK1-mediated phosphorylation³³ CDK1-mediated phosphorylation
Cyclin-dependent kinase 1, the master regulator of mitosis. When CDK1 phosphorylates NIPA at Ser-395, it inactivates NIPA, allowing cyclin-B1 to accumulate and mitosis to proceed.

The R363H substitution alters this regulatory circuit. In cells carrying the risk C allele (Arg363), CDK1-mediated phosphorylation at Ser-395 is significantly slower (p=0.002), meaning NIPA remains active longer. Active NIPA holds cyclin-B1 out of the nucleus, reducing its stability there and slowing nuclear accumulation. The net result: risk-allele cells take approximately 3.4 additional minutes to complete mitosis compared to protective-allele cells (p=0.011).

The protective T allele (His363) shows a different phosphorylation profile. Functional validation using isogenic genome-edited cell lines⁴⁴ Functional validation using isogenic genome-edited cell lines
identical cells differing only at rs11556924 demonstrated that His363 NIPA has increased phosphorylation at Ser354, higher protein expression, and greater nuclear mobility — all consistent with faster inactivation and more permissive cell cycle control. Critically, His363 cells show reduced proliferation, which is the proposed mechanism of cardiovascular protection.

In vascular biology, the stakes are high. Vascular smooth muscle cells (VSMCs)⁵⁵ Vascular smooth muscle cells (VSMCs)
the primary cell type in the arterial wall undergo phenotypic switching from quiescent contractile cells to proliferative, migratory synthetic cells during atherogenesis. ZC3HC1 deficiency in VSMCs increases migration and promotes neointima formation — the hallmark of atherosclerotic plaque development — while also modulating cyclin-B1 levels and the SRF contractile gene program. Altered cell cycle control by the Arg363 variant may therefore sustain VSMC proliferation in the arterial wall, accelerating plaque growth.

The Evidence

The primary evidence comes from the CARDIoGRAM GWAS meta-analysis⁶⁶ CARDIoGRAM GWAS meta-analysis
Coronary ARtery DIsease Genome-wide Replication And Meta-analysis consortium, which combined 14 individual GWAS studies totaling 22,233 cases and 64,762 controls. Of the 13 newly identified loci, rs11556924 in ZC3HC1 was the sole coding variant, making it particularly tractable for functional follow-up. The OR of 0.90 per T allele is consistent across replication cohorts and represents a robustly replicated GWAS signal.

Beyond CAD, the C allele has been associated with hypertension in the Finnish TAMRISK cohort⁷⁷ hypertension in the Finnish TAMRISK cohort
769 participants at age 50, OR 1.42 for hypertension in CC carriers vs T allele carriers, 95% CI 1.10–1.84, suggesting effects on vascular function extend to blood pressure regulation. The T allele frequency varies markedly by ancestry: approximately 38% in Europeans, but only 5% in East Asians and 8% in Africans. This means about 43% of Europeans are homozygous CC, carrying the full two-dose risk.

The T allele frequency of 38% in Europeans means this is a common protective variant — the population-level effect is substantial. Each copy of the T allele reduces CAD risk by approximately 10%, and TT homozygotes (10% of Europeans) carry roughly 18% lower risk than CC homozygotes.

Practical Actions

The CAD-protective mechanism of the His363 variant operates through slower cell proliferation and altered VSMC phenotype. While carriers of the risk CC genotype cannot change their genotype, several interventions target the same cell cycle and vascular smooth muscle pathways implicated by this variant.

Monitoring cardiovascular risk factors — particularly blood pressure — is especially relevant for CC carriers. The TAMRISK data link CC to elevated hypertension risk, and blood pressure control is one of the most effective ways to reduce atherosclerotic progression independent of the genetic mechanism.

Omega-3 fatty acids (EPA and DHA) modulate VSMC phenotype and reduce proliferation through mechanisms that overlap with the ZC3HC1/cyclin-B1 pathway, including suppression of VSMC migration. Aspirin and antiplatelet therapy may also address the platelet-function dimensions of this variant's cardiovascular effects.

Interactions

ZC3HC1 operates within the broader cell cycle control network. The CDK1 pathway that phosphorylates NIPA is regulated by multiple upstream signals, and variants in cell cycle checkpoint genes could theoretically compound or mitigate ZC3HC1's effects. However, no published compound-action evidence currently exists for this specific interaction.

For cardiovascular risk, ZC3HC1 rs11556924 adds to polygenic scores alongside established CAD loci including rs4977574 (CDKN2A/B), rs9349379 (PHACTR1), and rs1333049 (9p21). These loci act through independent mechanisms — the 9p21 locus affects CDKN2A/B (cell cycle inhibitors), creating a potential directional interaction: individuals carrying risk alleles at both the 9p21 locus and ZC3HC1 face additive CAD risk through converging cell cycle dysregulation, though quantified compound-genotype risk estimates are not yet available in the published literature.

Most people think of gout as a disease of diet — too much red meat, beer, or shellfish. That is partly true. But your kidneys' ability to excrete uric acid is equally determined by genetics, and one of the less obvious players is ALPK1¹¹ ALPK1
Alpha-kinase 1, a serine/threonine kinase that serves as a cytosolic innate immune sensor for bacterial metabolites and also regulates urate transport in the kidney. ALPK1 encodes a kinase best known as the master switch of the ALPK1-TIFA-NF-κB signaling axis²² ALPK1-TIFA-NF-κB signaling axis
A cellular alarm system: ALPK1 detects bacterial metabolites (ADP-heptose), phosphorylates the adaptor protein TIFA, which then activates the pro-inflammatory transcription factor NF-κB, triggering cytokine production, the innate immune pathway that detects gram-negative bacterial metabolites and triggers inflammatory cytokine production. But ALPK1 also turns out to regulate URAT1³³ URAT1
The urate transporter 1, encoded by SLC22A12 — the primary transporter responsible for reabsorbing uric acid from urine back into the bloodstream in renal proximal tubules. Inhibiting URAT1 is the mechanism of the gout drug probenecid, the kidney protein responsible for reabsorbing urate from the urine back into the bloodstream. The Met861Thr variant (rs11726117, T>C on the plus strand) sits in the kinase domain of ALPK1 and disrupts this regulatory balance.

The Mechanism

ALPK1 normally acts as a negative regulator of URAT1 expression: higher ALPK1 activity suppresses URAT1, which reduces urate reabsorption and keeps serum uric acid lower. The C allele (Met861Thr) at rs11726117 is associated with altered ALPK1 function and, in kidney cells exposed to monosodium urate crystals⁴⁴ monosodium urate crystals
The needle-shaped crystals that form in joints and soft tissue when serum uric acid exceeds its solubility threshold (~6.8 mg/dL), triggering the acute inflammatory response of a gout attack, less effective suppression of URAT1 expression. The result is higher urate reabsorption, elevated serum uric acid, and increased susceptibility to both hyperuricemia and the inflammatory cascade that drives gout attacks.

The ALPK1 connection to inflammation matters beyond urate transport. ALPK1 phosphorylates TIFA⁵⁵ TIFA
TRAF6-interacting protein with a forkhead-associated domain — a molecular bridge between ALPK1 sensing and NF-κB activation, which in turn activates TRAF6 and NF-κB, triggering a cascade of pro-inflammatory cytokines. Monosodium urate crystals may tap into this same pathway, potentially amplifying joint inflammation in individuals whose ALPK1 variant produces a more reactive signaling state.

The Evidence

Ko et al.⁶⁶ Ko et al.
Ko AM et al. ALPK1 genetic regulation and risk in relation to gout. Int J Epidemiol, 2013 conducted a genome-wide association study of 1,351 Taiwanese aboriginal participants (511 gout cases, 840 controls) and found rs11726117 among the top hits, with the C allele carrying an odds ratio ≥1.44 (P ≤3.78×10⁻⁶). A replication in 511 Han Chinese participants confirmed the association, with OR ≥1.72 (P ≤4.08×10⁻³). The CC composite genotype with other ALPK1 variants showed OR = 1.83.

Kuo et al.⁷⁷ Kuo et al.
Kuo TM et al. URAT1 inhibition by ALPK1 is associated with uric acid homeostasis. Rheumatology (Oxford), 2017 provided functional evidence in 492 Han Chinese participants and a transgenic mouse model. ALPK1 overexpression significantly lowered URAT1 protein levels (P=0.0045), and the T allele at rs11726117 was associated with reduced gout risk via the SLC22A12 pathway (OR 0.39 — meaning T carriers have roughly 61% lower odds of gout versus C/C homozygotes in this model). Monosodium urate crystal exposure inhibited URAT1 expression through ALPK1 upregulation, suggesting a feedback loop that is disrupted by the Met861Thr variant.

Tu et al.⁸⁸ Tu et al.
Tu HP et al. Variants of ALPK1 with ABCG2, SLC2A9, and SLC22A12 increased the positive predictive value for gout. J Hum Genet, 2018 showed that combining ALPK1 CC with high-risk genotypes in ABCG2, SLC2A9, and SLC22A12 achieved a 99% positive predictive value for gout in Han Chinese (OR up to 55.0), underscoring the importance of ALPK1 in a polygenic gout risk model.

However, a Japanese replication study⁹⁹ Japanese replication study
Chiba T et al. Common variant of ALPK1 is not associated with gout: a replication study. Hum Cell, 2015 in 903 gout cases and 1,302 controls found no significant association (minor allele frequency 0.26 vs 0.25, p=0.44), suggesting the effect may be population-specific or modified by linkage disequilibrium differences between ethnic groups. This limits the evidence level to moderate.

Practical Actions

For individuals with the risk genotype (CC or CT), the most actionable implication is heightened attention to urate management. The ALPK1-URAT1 pathway points toward renal urate handling as the primary mechanism — meaning dietary strategies that reduce the urate load reaching the kidneys and pharmacological URAT1 inhibitors (when clinically indicated) are the most directly relevant interventions.

Monitoring serum uric acid is the first step: knowing your baseline uric acid level tells you whether ALPK1 genotype is translating into biochemical risk. Target below 6 mg/dL to prevent crystal formation, below 5 mg/dL if you have had prior gout attacks.

Interactions

The strongest interactions documented in the literature are with the major urate transporter genes: rs2231142 in ABCG2 (the intestinal urate exporter), rs505802 in SLC22A12/URAT1 (renal urate reabsorption), and rs3825016 in SLC22A12. Tu et al. (2018) showed that stacking ALPK1 CC with CC homozygosity at ABCG2 rs2231142 and risk alleles at SLC2A9 and SLC22A12 raised the predictive value for gout to near certainty. These compound effects reflect how urate metabolism is governed by a network of transporters — ALPK1 appears to be a regulatory node that amplifies or dampens the net effect of this transporter ensemble.

Your cells run on fat during fasting, prolonged exercise, and sleep. The first step of burning very long-chain fatty acids — chains of 14 to 20 carbons — depends on very long-chain acyl-CoA dehydrogenase (VLCAD)¹¹ very long-chain acyl-CoA dehydrogenase (VLCAD)
encoded by ACADVL on chromosome 17p13; the enzyme catalyzes the alpha,beta-dehydrogenation of fatty acyl-CoA esters in the inner mitochondrial membrane, the enzyme encoded by ACADVL. When both copies of this gene are severely disrupted, VLCAD deficiency (VLCADD) results — a rare inborn error of metabolism that can cause hypertrophic cardiomyopathy in infancy, hypoglycemia during fasting, or exercise-induced muscle breakdown in adults. The rs118204017 variant creates a phenylalanine-to-leucine substitution at residue 458, and has been classified as likely pathogenic²² classified as likely pathogenic
ClinVar VCV000001632; reviewed by the ClinGen ACADVL Variant Curation Expert Panel, 3-star review status, December 2022 by the ClinGen ACADVL Expert Panel. At a population frequency of roughly 1 in 40,000 chromosomes in gnomAD, it is exceptionally rare — meaning most people who carry one copy will never meet a partner who carries the same or another ACADVL variant.

The Mechanism

ACADVL encodes a homodimeric flavoenzyme³³ homodimeric flavoenzyme
VLCAD is a 70 kDa subunit homodimer anchored to the inner mitochondrial membrane; it works in concert with the mitochondrial trifunctional protein (MTP) to complete each cycle of fatty acid beta-oxidation that anchors to the inner mitochondrial membrane. Phenylalanine 458 sits within the acyl-CoA substrate binding channel of the mature enzyme. The substitution to leucine changes the shape of this channel, reducing catalytic efficiency for very long-chain substrates. Unlike null variants (frameshifts, nonsense, splice-site mutations) that abolish enzyme production entirely, missense variants like p.Phe458Leu typically preserve partial residual activity — estimated at roughly 20% of normal in one functional study — which is why homozygosity or compound heterozygosity for this variant tends to produce a milder clinical presentation than loss-of-function alleles. In a single heterozygous carrier, the one intact ACADVL copy produces sufficient enzyme for completely normal fatty acid oxidation.

The Evidence

The variant was first identified by Cox et al. in 1998⁴⁴ Cox et al. in 1998
Cox GF et al., J Pediatr 133:247–53 in an infant who presented at 5 months with severe hypertrophic cardiomyopathy, hepatomegaly, encephalopathy, and hypotonia — compound heterozygous for p.Phe458Leu on one allele and a splice site mutation on the other. The cardiomyopathy resolved substantially within one year on a low long-chain fat diet supplemented with medium-chain triglyceride (MCT) oil and carnitine, demonstrating that VLCADD-related cardiomyopathy is treatable when identified early.

The genotype-phenotype landscape was mapped by Andresen et al. 1999⁵⁵ Andresen et al. 1999
PMID 9973285, AJHG 64:479–494 across 55 unrelated patients with all clinical forms of VLCADD. Patients with severe early-onset disease consistently carried null variants on both alleles; those with the milder hepatic or adult myopathic forms carried at least one missense allele with residual enzyme activity. This genotype-severity correlation is significantly stronger in VLCADD than in the related MCAD deficiency, making variant classification clinically useful for anticipating prognosis. A large U.S. newborn screening cohort⁶⁶ large U.S. newborn screening cohort
Miller et al. 2015, PMID 26385305, Mol Genet Metab 116:139–45 of 693 VLCAD-screen-positive infants found that approximately 57% carried only a single ACADVL pathogenic variant, emphasizing that heterozygous carrier detection is an inherent feature of population-based newborn screening for this condition.

Practical Implications

Single-copy carriers of p.Phe458Leu are metabolically normal and require no dietary modifications or monitoring. The clinical relevance is entirely reproductive: if both partners in a couple carry a pathogenic ACADVL variant — whether this variant or any other — each pregnancy has a 25% chance of producing a child with VLCAD deficiency. Because VLCADD is an autosomal recessive disorder with an estimated birth prevalence of 1 in 30,000–100,000, the chance that a random partner is also an ACADVL carrier is roughly 1 in 100–200. Carrier couple identification before pregnancy allows access to prenatal testing, preimplantation genetic testing (PGT), or informed expectant management.

VLCADD identified early — through newborn screening or family cascade testing — is highly treatable. Management centers on reducing dependence on very long-chain fat oxidation: a diet low in long-chain triglycerides (LCT) with MCT supplementation, strict avoidance of fasting, and L-carnitine supplementation in some cases. Triheptanoin (C7 fat), an odd-chain anaplerotic MCT, received FDA approval in 2020 for the management of long-chain fatty acid oxidation disorders including VLCADD. Outcomes for newborn-screen-identified infants treated from birth are substantially better than for those diagnosed after symptom onset.

Interactions

rs118204017 is one of many pathogenic ACADVL variants; rs118204015⁷⁷ rs118204015 is a second ACADVL variant in this GeneOps batch. Compound heterozygosity for two ACADVL pathogenic variants — one on each chromosome — produces VLCAD deficiency in the same way as homozygosity; the severity depends on the residual enzyme activity of the two alleles combined. Compound heterozygosity for p.Phe458Leu and a null allele (the scenario in the original Cox 1998 case) produces a more severe phenotype than two missense alleles with partial residual activity. Carriers of rs118204017 who are also carriers of rs118204015 (or any other pathogenic ACADVL variant) on the opposite chromosome would be affected individuals, not unaffected carriers.